The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.
Study Type
OBSERVATIONAL
Enrollment
1,247
Novartis
East Hanover, New Jersey, United States
Number of Patients by Patient Characteristic
Patient characteristics included: * Age * Race * Marital status * Insurance status * Practice type * Physician specialty * Geographic region * Have a Gleason score ≤1 year of index * Gleason score (\<7, ≥7) * Have a prostate-specific antigen (PSA) test ≤1 year of index * PSA level (elevated, normal, unknown)
Time frame: Baseline
Mean PSA Level
Time frame: Baseline
Number of Patients by Number of ARPIs and Taxanes Received Before 177Lu-PSMA-617 Treatment Initiation
Time frame: Baseline
Number of Patients by Number of Doses of 177Lu-PSMA-617 Treatment From Initiation Until Discontinuation
Time frame: Up to approximately 2 years
Duration of 177Lu-PSMA-617 Treatment
Time frame: Up to approximately 2 years
Number and Percentage of Patients Initiating ARPIs, Taxanes, and Other Guideline-recommended Therapies for mCRPC After 177Lu-PSMA-617 Discontinuation
Time frame: Up to approximately 2 years
Number and Percentage of Patients With a Reduction in PSA Level
Reduction in PSA level was categorized as follows: * ≥50% (PSA50) reduction in PSA level * ≥80% (PSA80) reduction in PSA level * ≥90% (PSA90) reduction in PSA level
Time frame: Baseline up to approximately 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.